<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01123187</url>
  </required_header>
  <id_info>
    <org_study_id>CP 95/120</org_study_id>
    <secondary_id>98001</secondary_id>
    <secondary_id>DGS 980032</secondary_id>
    <nct_id>NCT01123187</nct_id>
  </id_info>
  <brief_title>Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation</brief_title>
  <official_title>Phase 2 Study of Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation With Steroid Free Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single center phase 2 clinical trial, is designed for confirming the efficacy and safety&#xD;
      of sequential islet allotransplantation with steroid free immunosuppression in patients with&#xD;
      previous kidney transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The beneficial effects of glycemic control on both survival and function of transplanted&#xD;
      kidneys in patients with type 1 diabetes mellitus have been recognized.&#xD;
&#xD;
      The purpose of this study is to reverse hyperglycemia and insulin dependency, by islet cell&#xD;
      transplantation, in patients with type 1 diabetes mellitus who have a stable kidney&#xD;
      allograft.&#xD;
&#xD;
      The study primary efficacy endpoint is graft survival defined as insulin independence and&#xD;
      HbA1c &lt; 8% at 1 year post first transplant. Secondary outcomes are graft function and&#xD;
      metabolic control&#xD;
&#xD;
      The immunosuppression protocol for the kidney graft was converted to sirolimus+tacrolimus&#xD;
      regimen 6 months before islet transplantation to exclude negative effects on kidney graft&#xD;
      function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Islet transplantation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite criteria: insulin independence and Glycosylated Hemoglobin (HbA1c) under 8% at one year after the transplantation</measure>
    <time_frame>One year</time_frame>
    <description>Percent of insulin-independent patients with a Glycosylated Hemoglobin (HbA1c) under 8% at one year after injection of approximately 10,000 islets equivalents / kg (IE/kg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>The number of adverse events related to the procedure and to the immunosuppression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of severe episodes of hypoglycemia</measure>
    <time_frame>1 year</time_frame>
    <description>Number of severe episodes of hypoglycemia (requiring the use of third)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Diabetes complications</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of Diabetes complications: retinopathy, neuropathy, nephropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism</measure>
    <time_frame>1 year</time_frame>
    <description>Lipid metabolism assessed by measurement of total cholesterol and HDL cholesterol, triglycerides, ApoA1, apoB, apoE, free fatty acids and lipid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of kidney function</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of kidney function (creatinine, creatinine clearance,proteinurie)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Organ Transplantation</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>islet transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Islet transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>islet transplantation</intervention_name>
    <description>Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.</description>
    <arm_group_label>islet transplantation</arm_group_label>
    <other_name>surgical catheterisation</other_name>
    <other_name>percutaneous catheterisation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus. Documentation of negative basal and stimulated C-peptide and&#xD;
             diagnosis of diabetes for at least 5 years.&#xD;
&#xD;
          -  Recipient of renal transplant with good function (creatinine clearance &gt;/=60 ml/min)&#xD;
&#xD;
          -  Stable immunosuppression consisting of any combination of sirolimus, tacrolimus for at&#xD;
             least 6 months, without major complications&#xD;
&#xD;
          -  Ability to give informed consent.&#xD;
&#xD;
          -  Age greater than or equal to 18 years or less than or equal to 65 years&#xD;
&#xD;
          -  No evidence of liver disease (liver enzymes &lt; twice the upper limit of normal)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age below 18 years and above 65 years&#xD;
&#xD;
          -  Significant cardiovascular disease, including non-correctable coronary artery disease&#xD;
             and/or recent myocardial infarction(within last 12 months); extensive peripheral&#xD;
             vascular disease not correctable by surgery, unstable angina&#xD;
&#xD;
          -  Untreated proliferative retinopathy.&#xD;
&#xD;
          -  Recent Cerebrovascular accident (within last 12 months)&#xD;
&#xD;
          -  Recent unresolved acute infection, or chronic infection, including tuberculosis, HIV,&#xD;
             HBV, HCV, CMV or positive skin test for TB&#xD;
&#xD;
          -  Any history of malignancy, except squamous or basal skin cancer or in situ cancer of&#xD;
             the cervix.&#xD;
&#xD;
          -  History of non-compliance, or inability to demonstrate capacity to comply with strict&#xD;
             blood glycemic control and insulin pump therapy.&#xD;
&#xD;
          -  Psychiatric illness that is untreated, or likely to interfere significantly with&#xD;
             transplantation despite treatment.&#xD;
&#xD;
          -  Pregnant women, women intending future pregnancy, women of reproductive potential who&#xD;
             are unable or unwilling to follow effective contraceptive measures for the duration of&#xD;
             immunosuppressive therapy&#xD;
&#xD;
          -  Fasting C-peptide &gt; 0.2 ng/ml&#xD;
&#xD;
          -  Creatinine &gt; 25mg/l&#xD;
&#xD;
          -  Alkaline phosphatase, total bilirubin, Alanine Aminotransferase (ALT)or Aspartate&#xD;
             Aminotransferase (AST) &gt; twice the upper limit of normal&#xD;
&#xD;
          -  Significant liver disease (elevation of liver enzymes &gt; twice the upper limit of&#xD;
             normal for each of ALT and AST, liver masses including portal vein thrombosis,&#xD;
             evidence of portal hypertension, or significant, untreated gallbladder disease (i.e.,&#xD;
             gallstones).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François PATTOU, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Christine VANTYGHEM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian NOEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julie KERR-CONTE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Lille 2</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>May 11, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes type 1</keyword>
  <keyword>kidney transplantation</keyword>
  <keyword>islet</keyword>
  <keyword>hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

